10,991 Shares in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,991 shares of the company’s stock, valued at approximately $31,000.

Separately, Ground Swell Capital LLC bought a new position in shares of MAIA Biotechnology in the second quarter worth approximately $56,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Trading Down 1.0 %

Shares of NYSEAMERICAN MAIA opened at $2.02 on Monday. MAIA Biotechnology, Inc. has a 52 week low of $0.98 and a 52 week high of $5.99. The firm has a market capitalization of $51.17 million, a P/E ratio of -1.46 and a beta of 0.14.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.21. On average, analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.

Insider Activity at MAIA Biotechnology

In related news, Director Stan Smith purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $1.87 per share, with a total value of $46,750.00. Following the completion of the purchase, the director now directly owns 1,130,060 shares in the company, valued at approximately $2,113,212.20. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cristian Luput acquired 22,133 shares of the business’s stock in a transaction on Friday, November 1st. The shares were purchased at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the transaction, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. This represents a 6.03 % increase in their position. The disclosure for this purchase can be found here. 36.98% of the stock is owned by company insiders.

MAIA Biotechnology Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.